98%
921
2 minutes
20
Population ageing within Europe has major social and economic consequences. One of the most devastating conditions that predominantly affects older people is dementia. The SMART4MD (Support Monitoring and Reminder Technology for Mild Dementia) project aims to develop and test a health application specifically designed for people with mild dementia. The aim of this feasibility study was to evaluate the design of the SMART4MD protocol, including recruitment, screening, baseline examination and data management, and to test the SMART4MD application for functionality and usability before utilization in a full-scale study. The feasibility study tested the protocol and the app in Spain and Sweden. A total of nineteen persons with cognitive impairment, and their informal caregivers, individually performed a task-based usability test of the SMART4MD app model in a clinical environment, followed by four-week testing of the app in the home environment. By employing a user-centered design approach, the SMART4MD application proved to be an adequate and feasible interface for an eHealth intervention. In the final usability test, a score of 81% satisfied users was obtained. The possibility to test the application in all the procedures included in the study generated important information on how to present the technology to the users and how to improve these procedures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557766 | PMC |
http://dx.doi.org/10.3390/ijerph17186816 | DOI Listing |
J Alzheimers Dis
September 2025
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
As plasma biomarkers like p-tau217 move towards clinical use in Alzheimer's disease (AD), it is important to understand how kidney function may influence their accuracy. Even mild chronic kidney disease (CKD) can alter biomarker levels, potentially impacting test performance. While accounting for renal function may improve specificity, it could reduce sensitivity without greatly changing overall diagnostic accuracy.
View Article and Find Full Text PDFJ Korean Med Sci
September 2025
Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea.
Background: Neuropsychological assessments are critical to cognitive care, but are time-consuming and often of variable quality. Automated tools, such as ReadSmart4U, improve report quality and consistency while meeting the growing demand for cognitive assessments.
Methods: This retrospective cross-sectional study analysed 150 neuropsychological assessments stratified by cognitive diagnosis (normal cognition, mild cognitive impairment and Alzheimer's disease) from the Clinical Data Warehouse of a university-affiliated referral hospital (2010-2020).
Alzheimers Dement
September 2025
Boston University Alzheimer's Disease Research Center and BU CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
We describe the rationale, methodology, and design of the Boston University Alzheimer's Disease Research Center (BU ADRC) Clinical Core (CC). The CC characterizes a longitudinal cohort of participants with/without brain trauma to characterize the clinical presentation, biomarker profiles, and risk factors of post-traumatic Alzheimer's disease (AD) and AD-related dementias (ADRD), including chronic traumatic encephalopathy (CTE). Participants complete assessments of traumatic brain injury (TBI) and repetitive head impacts (RHIs); annual Uniform Data Set (UDS) and supplementary evaluations; digital phenotyping; annual blood draw; magnetic resonance imaging (MRI) and lumbar puncture every 3 years; electroencephalogram (EEG); and amyloid and/or tau positron emission tomography (PET) on a subset.
View Article and Find Full Text PDFAm J Med Genet A
September 2025
Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome. To evaluate the functionality of the NTG-EDSD for Dementia as part of a dementia screening protocol for adults with Down syndrome, we conducted a cohort analysis of patients aged 40 and older followed at the Massachusetts General Hospital Down Syndrome Program, noting any clinical interpretation of dementia or mild cognitive impairment (MCI). From September 2023 to September 2024, 54 NTG-EDSD responses were collected.
View Article and Find Full Text PDFSleep Adv
August 2025
Division of Public Health, Department of Family and Preventive Medicine, University of Utah, 303 Chipeta Way, Salt Lake City, UT 84013, United States of America.
Individuals with mild cognitive impairment (MCI) demonstrate cognitive decline without major functional impairment and are at increased risk for developing Alzheimer's disease and related dementias (ADRD). Sleep and biobehavioral rhythm disturbances (disruptions in 24-h oscillations in physiology and behavior, including rest-activity patterns and mealtimes) are more than twice as common among patients with MCI than cognitively intact older adults. Importantly, the consequences of sleep and biobehavioral rhythm disruption in MCI extend beyond the patient, also profoundly affecting the spouse/partner.
View Article and Find Full Text PDF